Managing Atopic Dermatitis with Dupilumab in Special Populations: A Case Series Study
Dupilumab shows promise for managing AD in SP, but careful monitoring and further research are necessary to address safety concerns and optimize treatment strategies. Larger studies with longer follow-ups are needed to fully evaluate its safety and efficacy in SP and those with comorbidities. These findings support the need for personalized treatments and ongoing research to enhance outcomes in patients with complex medical histories.
Authors
- Nicoletta Bernardini (ORCID: https://orcid.org/0000-0002-6295-3574)
- Antonio Di Guardo (ORCID: https://orcid.org/0000-0002-0117-346X)
- Nevena Skroza (ORCID: https://orcid.org/0000-0003-4478-5404)
- Concetta Potenza (ORCID: https://orcid.org/0000-0002-6300-8697)
- Ilaria Proietti (ORCID: https://orcid.org/0000-0003-3795-3190)
- Ersilia Tolino (ORCID: https://orcid.org/0000-0001-7861-9338)
Institutions
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Clinical Cosmetic and Investigational Dermatology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.2147/ccid.s508359
- Citations
- 1
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.00